Poly ICLC

Poly ICLC
Clinical data
ATC code	L03AX08 (WHO) ;
Identifiers
ChemSpider	none;
	(verify)

Poly ICLC is an immunostimulant. It is polyinosinic-polycytidylic acid (poly I:C) mixed with the stabilizers carboxymethylcellulose and polylysine.^[1] It is under trial for use in cancer.^[2]

Poly I:C is a ligand for toll like receptor-3, which usually triggers on the structurally similar double-stranded RNA present in some viruses.^[1]

References

^ ^a ^b Zhu X, Nishimura F, Sasaki K, et al. (2007). "Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models". Journal of Translational Medicine. 5: 10. doi:10.1186/1479-5876-5-10. PMC 1802742. PMID 17295916.
^ "Intervention Dynamic Trial Listing Page". National Cancer Institute. 13 June 2017.

External links

National Cancer Institute: poly ICLC

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Poly_ICLC
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[pmid17295916-1] Zhu X, Nishimura F, Sasaki K, et al. (2007). "Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models". Journal of Translational Medicine. 5: 10. doi:10.1186/1479-5876-5-10. PMC 1802742. PMID 17295916.

[2] "Intervention Dynamic Trial Listing Page". National Cancer Institute. 13 June 2017.

[1]

[2]